JP5546867B2 - ホルシチアシド注射製剤 - Google Patents
ホルシチアシド注射製剤 Download PDFInfo
- Publication number
- JP5546867B2 JP5546867B2 JP2009543329A JP2009543329A JP5546867B2 JP 5546867 B2 JP5546867 B2 JP 5546867B2 JP 2009543329 A JP2009543329 A JP 2009543329A JP 2009543329 A JP2009543329 A JP 2009543329A JP 5546867 B2 JP5546867 B2 JP 5546867B2
- Authority
- JP
- Japan
- Prior art keywords
- forsythiaside
- injection
- added
- water
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- DTOUWTJYUCZJQD-UJERWXFOSA-N Forsythiaside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H](O)[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O1 DTOUWTJYUCZJQD-UJERWXFOSA-N 0.000 title claims description 95
- DTOUWTJYUCZJQD-QJDQKFITSA-N Forsythiaside Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](OCCc3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O DTOUWTJYUCZJQD-QJDQKFITSA-N 0.000 title claims description 92
- 239000007924 injection Substances 0.000 title claims description 69
- 238000002347 injection Methods 0.000 title claims description 69
- 239000000203 mixture Substances 0.000 title claims description 11
- 238000009472 formulation Methods 0.000 title claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 239000008215 water for injection Substances 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 30
- 239000008176 lyophilized powder Substances 0.000 claims description 29
- 238000004108 freeze drying Methods 0.000 claims description 28
- 239000000463 material Substances 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 11
- 238000000108 ultra-filtration Methods 0.000 claims description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000001471 micro-filtration Methods 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 46
- 238000012360 testing method Methods 0.000 description 24
- 238000003756 stirring Methods 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 238000001802 infusion Methods 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- FYKDNWHPKQOZOT-UHFFFAOYSA-M sodium;dihydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OP(O)([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FYKDNWHPKQOZOT-UHFFFAOYSA-M 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- 239000012266 salt solution Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000470 constituent Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000012982 microporous membrane Substances 0.000 description 8
- 239000002510 pyrogen Substances 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000001754 anti-pyretic effect Effects 0.000 description 6
- 239000002221 antipyretic Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 5
- 241000555712 Forsythia Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 description 4
- WBZKQQHYRPRKNJ-UHFFFAOYSA-N disulfurous acid Chemical compound OS(=O)S(O)(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-N 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- QBYMCVQZZZQPHE-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;calcium Chemical compound [Ca].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O QBYMCVQZZZQPHE-UHFFFAOYSA-N 0.000 description 3
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- XFSFBFKQBVFWHX-UHFFFAOYSA-L [Na+].[Na+].[O-]C([O-])=O.OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O Chemical compound [Na+].[Na+].[O-]C([O-])=O.OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O XFSFBFKQBVFWHX-UHFFFAOYSA-L 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 230000005496 eutectics Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610148180 | 2006-12-28 | ||
| CN200610148180.3 | 2006-12-28 | ||
| PCT/CN2007/003757 WO2008086698A1 (en) | 2006-12-28 | 2007-12-24 | A forsythoside injection and preparation thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514706A JP2010514706A (ja) | 2010-05-06 |
| JP2010514706A5 JP2010514706A5 (cg-RX-API-DMAC7.html) | 2011-02-17 |
| JP5546867B2 true JP5546867B2 (ja) | 2014-07-09 |
Family
ID=39609619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543329A Expired - Fee Related JP5546867B2 (ja) | 2006-12-28 | 2007-12-24 | ホルシチアシド注射製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100317604A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2113252A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5546867B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101117861B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101209255B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007344604A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008086698A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919869B (zh) * | 2009-06-16 | 2013-06-05 | 上海医药工业研究院 | 一种连翘酯苷a药物组合物 |
| CN103054884B (zh) * | 2011-10-18 | 2015-11-04 | 鲁南制药集团股份有限公司 | 连翘酯苷在制备抗副流感病毒药物中的用途及其制剂 |
| CN103054885A (zh) * | 2011-10-18 | 2013-04-24 | 鲁南制药集团股份有限公司 | 连翘酯苷在制备抗甲型h1n1病毒药物中的用途及其制剂 |
| CN102512371A (zh) * | 2012-01-09 | 2012-06-27 | 北京农学院 | 一种连翘酯苷脂质体的制备方法 |
| KR102201194B1 (ko) * | 2013-11-18 | 2021-01-12 | 주식회사 엘지생활건강 | 피부 재생, 주름 개선, 항염증 또는 피부 미백용 조성물 |
| CN105168372A (zh) * | 2015-10-16 | 2015-12-23 | 山西大学 | 连翘叶或其组分在制备减肥制品中的应用 |
| CN112946113B (zh) * | 2021-02-01 | 2022-09-30 | 湖北医药学院 | 一种鉴别道地药材十堰连翘基源的方法 |
| CN114990054B (zh) * | 2022-07-22 | 2023-07-21 | 成都艾伟孚生物科技有限公司 | 一种辅助生殖用洗精受精液 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1032876C (zh) * | 1991-08-12 | 1996-09-25 | 兖州矿务局科研所 | 高潜水塌陷区抗变形可搬迁房屋 |
| US6083921A (en) * | 1998-01-12 | 2000-07-04 | Xu; Kai Jian | Pharmaceutical compositions and method of using same |
| JP3882106B2 (ja) * | 2000-12-06 | 2007-02-14 | 三栄源エフ・エフ・アイ株式会社 | 退色抑制剤 |
| US6953786B2 (en) * | 2002-10-01 | 2005-10-11 | The Regents Of The University Of California | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
| JP2006188436A (ja) * | 2004-12-28 | 2006-07-20 | Japan Science & Technology Agency | 医用ポリフェノール溶液 |
-
2007
- 2007-11-27 CN CN2007101932272A patent/CN101209255B/zh active Active
- 2007-12-24 EP EP07846011A patent/EP2113252A4/en not_active Withdrawn
- 2007-12-24 US US12/521,494 patent/US20100317604A1/en not_active Abandoned
- 2007-12-24 WO PCT/CN2007/003757 patent/WO2008086698A1/zh not_active Ceased
- 2007-12-24 KR KR1020097015858A patent/KR101117861B1/ko not_active Expired - Fee Related
- 2007-12-24 JP JP2009543329A patent/JP5546867B2/ja not_active Expired - Fee Related
- 2007-12-24 AU AU2007344604A patent/AU2007344604A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010514706A (ja) | 2010-05-06 |
| EP2113252A4 (en) | 2012-10-31 |
| WO2008086698A1 (en) | 2008-07-24 |
| CN101209255A (zh) | 2008-07-02 |
| US20100317604A1 (en) | 2010-12-16 |
| KR101117861B1 (ko) | 2012-03-14 |
| KR20090095668A (ko) | 2009-09-09 |
| EP2113252A1 (en) | 2009-11-04 |
| AU2007344604A1 (en) | 2008-07-24 |
| CN101209255B (zh) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5546867B2 (ja) | ホルシチアシド注射製剤 | |
| JP2010514706A5 (cg-RX-API-DMAC7.html) | ||
| AU2017422167B2 (en) | Preparation of Pulsatilla saponin B4 for injection | |
| KR101529279B1 (ko) | 갓 추출물을 유효성분으로 함유하는 간독성 질환 예방 또는 치료용 약학 조성물 | |
| US7534457B2 (en) | Hemostatic mistura of ipomoea balatas leaves, methods of preparation and use thereof | |
| US20160227829A1 (en) | Dietary composition containing cistanche deserticola polysaccharide with inhibitory effects on colon cancer | |
| RU2500396C2 (ru) | Средство, обладающее кардиопротекторным действием, и способ его получения | |
| KR20180118413A (ko) | 밀리타리스 동충하초 부탄올 분획물을 유효성분으로 하는 간암의 예방 또는 치료용 조성물 | |
| KR101988757B1 (ko) | 1,2-디하이드록시-3-메틸안트라퀴논을 유효성분으로 하는 간암 예방 또는 치료용 조성물 | |
| CN100396289C (zh) | 灯盏花乙素注射制剂及其制备方法 | |
| CN100525759C (zh) | 一种用于治疗缺血性脑血管疾病的中成药 | |
| KR101538055B1 (ko) | 우르시올이 제거된 옻 추출물의 제조방법 및 상기 방법으로 제조된 옻 추출물의 약침으로서의 용도 | |
| CN101756986A (zh) | 一种尼麦角林与烟酰胺的药物组合物及其制备方法 | |
| CN101297692B (zh) | 樟叶越橘苷的提取及其在健康产品中的应用 | |
| CN100496461C (zh) | 银杏总黄酮的精制方法及制备银杏达莫注射液的方法 | |
| CN100502886C (zh) | 一种治疗痛经的药物组合物及其制备方法 | |
| CN1454596A (zh) | 一种银杏叶提取物与双嘧达莫复方药物及其制备方法 | |
| CN1969871A (zh) | 抗病毒复方制剂及其制备方法、质控方法和应用 | |
| CN107510650A (zh) | 一种匹多莫德口服溶液及其制备方法 | |
| HK40081229A (en) | A traditional chinese medicine composition and preparation method and application thereof | |
| KR20180118412A (ko) | 밀리타리스 동충하초 에틸아세테이트 분획물을 유효성분으로 하는 간암의 예방 또는 치료용 조성물 | |
| CN115192645A (zh) | 一种中药组合物及其制备方法和应用 | |
| KR20130001348A (ko) | 왕겨 추출물을 포함하는 뇌 혈류량 증가용 조성물. | |
| KR20120056151A (ko) | 안정성이 향상된 누에 수번데기 동결건조물 함유 액상 조성물 | |
| KR20200089242A (ko) | 복합 추출물을 포함하는 이상지질혈증 예방, 개선 또는 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101224 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101224 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110727 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110727 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130108 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130408 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130415 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130507 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131008 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140207 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140219 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140422 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140514 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5546867 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |